The FDA recently delayed its decision to approve Donanemab, another monoclonal antibody. Donanemab has different properties than Lecanemab because it targets a different form of amyloid, but overall there is a similar benefit. There are other drugs under investigation in clinical trials, but results are a few years away.
To learn more about Alzheimer’s disease treatment and care at UCLA, please speak with your primary care doctor or call the UCLA Neurology Outpatient Clinic: 310-794-1195.
You can also visit our website to find a provider, schedule an appointment, and learn more about treatment and care options: www.uclahealth...
Негізгі бет Are there other Alzheimer's disease treatments?
Пікірлер